Five out of twelve phenotypes in this cluster are therapeutically targeted by drugs modulating cGMP-forming or cGMP-metabolizing enzymes, including NO donors in myocardial infarction, sGC stimulators and phosphodiesterase inhibitors (PDEi) in hypertension, and combined angiotensin II type 1 receptor blocker/neprilysin inhibitor (ARNI) in heart failure (see Fig. 1a for details). This evidence concerns the gene MME and myocardial infarction.